Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus
Novartis closed the day up in Zurich, gaining 0.57% to finish at 119.96 francs, while its U.S. ADRs advanced 1.54%, settling at $156.42.

Today’s highest-ranked model selections.